
Methods: We performed a retrospective cohort analysis of 14 hospitals enrolled in the Duke Antibiotic Stewardship Outreach Network to evaluate IV-PO switch efficiency for targeted drugs: azithromycin, ciprofloxacin, levofloxacin, moxifloxacin, doxycycline, linezolid, metronidazole, and voriconazole. Electronic medication administration records from inpatient units for calendar year 2014 were used to calculate the proportion of oral (PO)/total days of therapy (DOT) by targeted antimicrobial treatment course. Descriptive statistics were used to evaluate PO/total DOT by hospital and antimicrobial. Negative binomial regression was used to evaluate the effect of IV-PO switch policy and other possible predictors.
Results: Seven of 14 hospitals had an IV-PO switch policy. A total of 57,413 courses of targeted antimicrobials were evaluated. PO route was used for roughly a third of antibiotic treatment days and ranged widely among hospitals (median 0.33, range 0.22-0.49). Distributions of PO/total DOT also varied by targeted antimicrobial. Doxycycline was most given by PO route (PO/total DOT 0.77); levofloxacin was least given by PO route (PO/total DOT 0.24). Treatment courses in hospitals with existing IV-PO switch policies had significantly greater PO/total DOT than those without a policy, although the effect was small (0.34 vs. 0.33, rate ratio 1.03, 1.00-1.06, p=0.04). Other significant predictors of PO/total DOT included hospital, antimicrobial, intensive care unit, and length of stay.
Conclusion: Overall, PO antimicrobial administration accounted for a third of DOT in this community hospital cohort. Hospitals with existing IV-PO switch policies more often used PO antimicrobials. While comparison studies such as this can help community hospitals assess use of IV-PO switches, hospital-level measures will require additional risk adjustment before interpretation.

B. Garner,
None
E. Dodds Ashley, None
M. Johnson, Astellas: Research Contractor , Research support
Charles River Laboratories: Research Contractor , Research support
UpToDate: Author , Royalties
IAS-¬USA: Speaker's Bureau , Speaker honorarium
R. H. Drew, UpToDate: Contributor , Publication royalty
American Society of Microbiology: Speaker's Bureau , Speaker honorarium
CustomID: Scientific Advisor , Licensing agreement or royalty
Independent Healthcare Education: Speaker's Bureau , Speaker honorarium
A. Davis, None
D. J. Sexton, None
D. Anderson, None
R. W. Moehring, None
See more of: Poster Abstract Session